Latest
Sources
Trade Ideas
Speakers
Sign in
Go
Foghorn Therapeutics CEO Talks Lilly-Partnered SMARCA2 Phase 1 and New Degrader Targets at Conference
Original source ↗
| February 14, 2026 at 00:03 UTC |
Finnhub - LLY
No analysis available.
Trade Ideas
Ticker
Direction
Speaker
Thesis
Time
LLY
LONG
Finnhub News
Foghorn Therapeutics' CEO discussed progress on a Lilly-partnered drug in Phase 1 and new drug targets, indicating pipeline advancement.
—